tiprankstipranks
Advertisement
Advertisement
Hims & Hers falls -10.3%
PremiumThe FlyHims & Hers falls -10.3%
7d ago
Hims & Hers Health: Regulatory Tailwinds and Peptide Opportunity Support Buy Rating, $40 Price Target Reiterated
Premium
Ratings
Hims & Hers Health: Regulatory Tailwinds and Peptide Opportunity Support Buy Rating, $40 Price Target Reiterated
7d ago
Canaccord Expects Hims & Hers Stock (HIMS) to Outperform ‘Major Indices by Several Hundred Basis Points.’ Here’s Why
Premium
Market News
Canaccord Expects Hims & Hers Stock (HIMS) to Outperform ‘Major Indices by Several Hundred Basis Points.’ Here’s Why
7d ago
Cboe data shows mixed options sentiment in Hims and Hers Health with shares down 3.25%
PremiumThe FlyCboe data shows mixed options sentiment in Hims and Hers Health with shares down 3.25%
9d ago
Hims & Hers app downloads reverse 10 month decline, says Morgan Stanley
Premium
The Fly
Hims & Hers app downloads reverse 10 month decline, says Morgan Stanley
9d ago
Hims & Hers Health Announces Accounting Officer Resignation
Premium
Company Announcements
Hims & Hers Health Announces Accounting Officer Resignation
14d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100